Aims/Introduction: Pronounced reduction of insulin secretion in response to a rise in glucose level has been reported in Japanese patients compared with Caucasian patients, but the mean body mass index (BMI) is also lower in Japanese patients. As BMI is a determinant of insulin secretion, we examined insulin-secretion capacity in obese and non-obese Japanese patients. Materials and Methods: Using the oral glucose tolerance test (OGTT), we estimated the insulin-secreting capacity in obese (BMI ‡ 25) and non-obese (BMI < 25) Japanese patients, including 1848 patients with normal glucose tolerance (NGT), 321 patients with impaired glucose tolerance (IGT) and 69 diabetes (DM) patients. Results: The insulinogenic index (I.I.), calculated by dividing the increment in serum insulin by the increment in plasma glucose from 0 to 30 min during OGTT, decreased from NGT to IGT and to DM in patients with and without obesity. In patients with NGT, IGT and DM, the I.I. values of obese patients were higher than those of the non-obese patients. The peak of insulin concentration in OGTT appeared at 60 min in NGT and at 120 min in IGT in both obese and non-obese patients, but in DM it was observed at 120 min in obese patients and at 60 min in non-obese patients. Conclusions: These results show that early-phase insulin secretion in obese Japanese patients is higher than in non-obese patients in all stages of glucose tolerance, and delayed insulin-secretion capacity is also conserved in obese Japanese patients, even in IGT and DM, which is similar to Caucasian patients. (J Diabetes Invest,
INTRODUCTION
Type 2 diabetes results from the deterioration of both insulin secretion and insulin action 1 , but the contribution of these factors to glucose intolerance varies among various ethnic groups. In Japan, reduced insulin-secreting capacity is considered to play a more important role than impaired insulin resistance during the transition from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT), and then to overt type 2 diabetes 2 . The insulinogenic index (I.I.) is calculated by dividing the increment in serum insulin from 0 to 30 min during an oral glucose tolerance test (OGTT) by the increment in plasma glucose during the same period. The I.I. is a marker of early-phase insulin-secretion capacity in response to a rise in blood glucose level 3 . A low I.I. has been described in Japanese patients, even in those with NGT or IGT, compared with Caucasian patients 4 .
The low I.I. in Japanese patients is thought to reflect b-cell fragility. We previously reported the positive association between body mass index (BMI) and I.I. in diabetic patients, and that BMI was an independent determinant of I.I. 5 . Because the average BMI is much lower in the Japanese than in Caucasians 6 , it is possible that the early-phase decrease in insulin secretion in the Japanese patients is partly a result of the lower BMI. To clarify the insulin-secretion capacity in obese and non-obese Japanese patients, we analyzed the insulin-secretion capacity measured by OGTT in subjects with NGT, IGT or DM, who were divided into those with and without obesity (BMI ‡ 25 or BMI < 25), and also estimated visceral fat area (eVFA) ‡ 100 cm 2 or eVFA < 100 cm 2 .
METHODS

Subjects
The study group comprised employees of Amagasaki City Office, Hyogo, Japan, an urban area, who had completed the government-funded annual health 8 . Serum insulin concentration was measured by double-antibody radioimmunoassay (Access insulin; Beckman Coulter, Brea, CA, USA) and was reported as immunoreactive insulin (IRI). Serum uric acid (UA), total cholesterol and triglyceride concentrations were measured by enzymatic methods. LDL and HDL cholesterol were also measured by enzymatic methods after heparin and calcium precipitation.
Detailed Examination
Visceral fat area (VFA) was determined by the bioelectrical impedance analysis (BIA) method, as reported previously 9 . In OGTT, plasma glucose (PG) and serum insulin concentrations were determined at 0, 30, 60 and 120 min after ingestion of 75 g of glucose. The I.I. was calculated by dividing the increment in serum insulin by the increment in PG from 0 to 30 min of the OGTT. Samples with I.I. <0 or ‡10 were excluded from the analysis, because they probably do not express the true early-phase insulin secretion in response to rise in PG. The area under the insulin curve during OGTT (AUC[insulin 0-120 ]) was calculated by the trapezoid rule. The diagnoses of diabetes, IGT and NGT were based on the criteria of the American Diabetes Association (ADA) 10 . Actually, NGT was defined as having FPG < 100 mg/dL and 2-h post-load glucose < 140 mg/dL. IGT was defined as having FPG < 126 mg/dL and 2-h post-load 
Statistical Analysis
Data are expressed as mean ± SD. Differences in variables between groups were tested with the unpaired Student's t-test. Statistical significance was considered at a P-value of <0.05. Table 1 lists the clinical characteristics of the BMI ‡ 25 and BMI < 25 groups with NGT, IGT and DM. The mean BMI of the entire BMI < 25 group was 22.9 ± 1.6 kg/m 2 , and that of the entire BMI ‡ 25 group was 27.6 ± 2.4 kg/m 2 . The insulin-secreting patterns during OGTT for the BMI ‡ 25 and BMI < 25 groups with NGT, IGT and DM are presented in Figure 1a -c, respectively. The IRI values at 0, 30, 60 and 120 min, and the AUC(insulin 0-120 ) were all significantly higher in the BMI ‡ 25 group than in the BMI < 25 group, including those with NGT, IGT and DM (Table 1 ). The insulinsecreting patterns between the BMI ‡ 25 and BMI < 25 groups with NGT, IGT or DM were also different; the peak IRI in NGT was noted at 60 min and that in IGT was recorded at 120 min in both groups, but the peak IRI in DM was observed at 120 min in the BMI ‡ 25 group, whereas at 60 min in the BMI < 25 group (Figure 1a-c) . Figure 2 shows data of the patients divided according to the VFA value (eVFA ‡ 100 and eVFA < 100). The IRI at 0, 30, 60 and 120 min were significantly higher in NGT and IGT subjects with eVFA ‡ 100 than those with eVFA < 100. However, in the eVFA ‡ 100 group with DM, only the IRI at 120 min was significantly higher than that of the eVFA < 100 group (Figure 2c) .
RESULTS
Next, we examined I.I. and homeostasis model of insulin resistance (HOMA-IR) in the BMI ‡ 25 and BMI < 25 groups with NGT, IGT and DM. The I.I. decreased from NGT to IGT and to DM in both the BMI ‡ 25 and BMI < 25 groups (Figure 3a) . The I.I. values of the BMI ‡ 25 groups were significantly higher than those of the BMI < 25 groups in each stage of glucose tolerance ( Table 1 ). The HOMA-IR increased from NGT to IGT and to DM in both the BMI ‡ 25 and BMI < 25 Table 1 ).
The I.I. values also decreased from NGT to IGT and to DM in both the eVFA ‡ 100 and eVFA < 100 groups (Figure 4a) . Furthermore, the I.I. values of the eVFA ‡ 100 group were significantly higher than those of the eVFA < 100 with NGT and IGT (NGT: 0.76 ± 0.70 vs 0.58 ± 0.64, P < 0.0001; IGT: 0.36 ± 0.33 vs 0.20 ± 0.16, P = 0.0016). The HOMA-IR values increased from NGT to IGT and to DM in both the eVFA ‡ 100 and eVFA < 100 groups (Figure 4b) . Furthermore, the HOMA-IR values of the eVFA ‡ 100 group were significantly higher than those of the eVFA < 100 group with NGT and IGT (NGT: 1.33 ± 0.77 vs 0.87 ± 0.46, P < 0.0001; IGT: 1.98 ± 1.58 vs 1.29 ± 0.86, P = 0.0035). In patients with DM, the I.I. and HOMA-IR values of the eVFA ‡ 100 group tended to be higher than those of the eVFA < 100 group, albeit insignificantly (I.I.: 0.24 ± 0.26 vs 0.16 ± 0.13, P = 0.3270; HOMA-IR: 2.42 ± 1.11 vs 1.94 ± 1.03, P = 0.2054).
We also analyzed 230 isolated IGT in our patients in order to compare them with those in the Botnia study, because that study showed only the data in isolated IGT, not in total IGT. Isolated IGT was defined as having FPG < 110 mg/dL and 2-h post-load glucose of 140-199 mg/dL according to the diagnostic criteria of the ADA guideline 1997. The insulin-secreting patterns were similar in all IGT subjects; that is, the peak IRI was recorded at 120 min in both the BMI ‡ 25 and BMI < 25 groups (57.4 ± 47.8 mU/mL vs 39.1 ± 23.4 mU/mL, P = 0.0017). The I.I. values of the BMI ‡ 25 and the BMI < 25 groups in our isolated IGT were 0.39 ± 0.37 and 0.29 ± 0.28 (BMI ‡ 25 vs BMI < 25, P = 0.0374), respectively. The I.I. value in obese Japanese patients with isolated IGT was lower than that in the Caucasian patients with isolated IGT from the literature 11 (0.39 ± 0.37 vs 0.77 ± 0.21, P < 0.01), although the mean BMI were not significantly different (28.0 ± 2.6 vs 27.4 ± 4.5). The HOMA-IR values of the BMI ‡ 25 and the BMI < 25 groups in our isolated IGT were 1.85 ± 1.71 and 1.25 ± 0.70 (BMI ‡ 25 vs BMI < 25, P = 0.0035), respectively. The HOMA-IR value in obese Japanese with isolated IGT was significantly lower than that in the Caucasian patients with isolated IGT (1.85 ± 1.71 vs 2.36 ± 2.00, P < 0.01).
DISCUSSION
Reduction in insulin-secretion capacity is considered to play a more important role than insulin resistance in the development to DM in Japanese patients. This is mainly supported by two facts. First, serum insulin levels during OGTT are lower in patients with IGT than those with NGT, and even lower in DM patients 4 . Second, the I.I. values are low throughout the development of glucose tolerance from NGT to IGT and to DM compared with Caucasians 4 . In the present study, we analyzed these issues in patients divided according to their BMI, and also according to the VFA value.
Our results showed significantly higher IRI values at 0, 30, 60 and 120 min, I.I. and AUC(insulin 0-120 ) in obese (BMI ‡ 25) than in non-obese (BMI < 25) patients with all stages of glucose tolerance. As shown in Table 1 , in the BMI ‡ 25 group, the AUC(insulin 0-120 ) of IGT was 1.22-fold higher than that of the NGT patients (5155 ± 3973 vs 4232 ± 2375) and that of the DM patients was almost 1.17-fold (4944 ± 2563) that of the NGT subjects. In addition, the peak level of IRI during OGTT in DM was noted at 120 min in the BMI ‡ 25 patients and 60 min in the BMI < 25 group. These observations show that the total and late insulin secretion during OGTT in obese patients does not decrease as much as in non-obese patients with NGT to IGT and to DM, and it is similar to the pattern in Caucasians. The previous report 4 that insulin concentrations during OGTT are lower in Japanese patients with IGT than those with NGT, and even lower in DM patients, does not match our obese group. These observations are also true when subjects are divided according to eVFA. It is not clear what causes the differences of insulin-secretion patterns between the obese and non-obese groups, but we believe they are b-cell capacity and visceral fat volume. Individuals who have a larger b-cell capacity could easily be developing visceral fat by overeating, leading to insulin resistance, deterioration of glucose tolerance and delayed hyperinsulin secretion in OGTT. In contrast, individuals who have a smaller b-cell capacity might not be developing so much visceral fat, but easily developing a deterioration of glucose tolerance owing to the decompensation of early-phase and then delayed-phase insulin secretion when overeating.
In order to examine whether it is also true in obese Japanese patients that early-phase insulin secretion is lower than Caucasian patients, we compared the I.I. in Japanese obese patients with isolated IGT with that in Caucasian patients with isolated IGT. The I.I. value in obese Japanese patients with isolated IGT was lower than that of the Caucasian patients with isolated IGT, although the mean BMI of them were not significantly different, suggesting decreased early-phase insulin secretion in obese, as well as non-obese, Japanese patients compared with Caucasian patients. In addition, the HOMA-IR value in obese Japanese patients with isolated IGT was lower than that in the Caucasian patients with isolated IGT. Together, with the lower I.I., these findings suggest that decreased early-phase insulin-secretion capacity plays a more important role than insulin resistance in the transition of IGT to DM, even in Japanese obese patients.
The present study had some study limitations. First, in screening patients, OGTT was carried out in subjects with one or more risk factor(s) as mentioned in the Methods section. Therefore, individuals with metabolic syndrome showing insulin resistance might be over represented in the present study, even in NGT. Actually, of the 1848 NGT patients in the present study, the number of individuals with BMI ‡ 25 was 1025 and the number of individuals with eVFA ‡ 100 was 1324. However, the mean HOMA-IR of non-obese patients in the NGT group was 0.96 and they showed no insulin resistance. We believe that non-obese patients in our NGT group could represent a control population. The second limitation was the comparison with the Botnia study. In the Botnia study, patients with known type 2 diabetes and their available family members were included. The study population was basically different from the present study population, including the male and female ratio. It might be that we cannot say the population of the Botnia Study is an appropriate one as a comparative study with the present study. In addition, comparison of mean BMI with Caucasian patients in the Botnia study might not be reasonable, as they did not separate the subjects with and without obesity. A comparative study with Caucasian patients in appropriate populations with matched BMI will be necessary in the future.
In conclusion, the present study showed that early-phase insulin secretion in obese Japanese patients is higher than in nonobese patients in all stages of glucose tolerance and the delayed insulin-secretion capacity is also conserved in obese Japanese patients, even in IGT and DM, which is similar to Caucasian patients.
